FirstWord

Trodelvy plus Keytruda secured a first-line nod in metastatic triple-negative breast cancer, while a regimen consisting of Enhertu plus Perjeta is recommended as a first-line treatment for HER2-positive metastatic breast cancer.

The EMA's drug advisory panel has also backed a trio of anti-cholesterol drugs and a first pharmacological treatment for cALD, while Zevra's contender for Niemann-Pick disease failed to get the panel's blessing.

Oral ileal bile acid transport inhibitor failed to improve native liver survival in patients undergoing Kasai surgery.

The decision ends regulatory filing plans for the OX40-ligand monoclonal antibody in the dermatologic indication.

The AI company highlighted rising demand for health-related queries and improved model performance.

Poster presentation builds on Phase 1b PP353 data published in The Lancet's eClinicalMedicine, reinforcing the rationale for a targeted, non-opioid approach to chronic Low Back Pain with Modic changes...

SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases,...

The presentation at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting marked the first time pooled Phase 3 data from the ADORING 1 and 2 trials on Validated Investigator Global Assessmen...

FirstWord spoke with Mount Sinai's Ranjan Duara about detailed Phase II CELIA data for diranersen from Biogen and Ionis, and what they suggest about it and other tau-targeting Alzheimer's therapies.

Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. ChemotherapyIvone...